Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Retirement Planning Co of New England Inc.

Key Points

• Retirement Planning Co of New England Inc. increased its stake in Teva Pharmaceutical Industries by 97.2% in Q1, owning 31,228 shares valued at $480,000.
• Several analysts have raised their price targets for Teva, with Goldman Sachs setting a target of $24.00 and JPMorgan Chase increasing theirs to $23.00.
• Teva reported $4.18 billion in revenue for the last quarter, slightly missing estimates, yet it beat earnings per share expectations with $0.66 per share.

Retirement Planning Co of New England Inc. boosted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 97.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,228 shares of the company's stock after acquiring an additional 15,393 shares during the quarter. Retirement Planning Co of New England Inc.'s holdings in Teva Pharmaceutical Industries were worth $480,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of TEVA. Canada Pension Plan Investment Board lifted its holdings in shares of Teva Pharmaceutical Industries by 109.2% during the first quarter. Canada Pension Plan Investment Board now owns 150,638 shares of the company's stock worth $2,315,000 after purchasing an additional 78,638 shares during the period. Iron Triangle Partners LP lifted its stake in shares of Teva Pharmaceutical Industries by 0.8% in the 1st quarter. Iron Triangle Partners LP now owns 2,217,730 shares of the company's stock worth $34,087,000 after acquiring an additional 17,694 shares during the period. Tema Etfs LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 12.5% in the first quarter. Tema Etfs LLC now owns 28,861 shares of the company's stock valued at $444,000 after acquiring an additional 3,199 shares in the last quarter. Trexquant Investment LP increased its stake in shares of Teva Pharmaceutical Industries by 114.8% during the first quarter. Trexquant Investment LP now owns 203,909 shares of the company's stock worth $3,134,000 after acquiring an additional 108,986 shares during the period. Finally, Lansforsakringar Fondforvaltning AB publ raised its holdings in Teva Pharmaceutical Industries by 2.2% during the first quarter. Lansforsakringar Fondforvaltning AB publ now owns 250,106 shares of the company's stock worth $3,844,000 after purchasing an additional 5,344 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Placid Jover sold 6,053 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares in the company, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded down $0.24 during midday trading on Thursday, reaching $18.53. 7,372,759 shares of the company were exchanged, compared to its average volume of 12,047,567. The firm's 50-day simple moving average is $16.95 and its 200-day simple moving average is $16.37. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market capitalization of $21.25 billion, a price-to-earnings ratio of -115.78, a P/E/G ratio of 1.09 and a beta of 0.72. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm's revenue for the quarter was up .3% compared to the same quarter last year. During the same period last year, the company earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analysts Set New Price Targets

TEVA has been the topic of a number of analyst reports. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Bank of America increased their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Finally, UBS Group cut their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of "Buy" and an average price target of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.